Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK

In a population-based case-control study of community-acquired Clostridium difficile–associated disease (CDAD), we matched 1,233 cases to 12,330 controls. CDAD risk increased 3-fold with use of any antimicrobial agent and 6-fold with use of fluoroquinolones. Prior use of antimicrobial agent did not...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaney, J. A. Chris, Dial, Sandra, Barkun, Alan, Suissa, Samy
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2007
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738472/
https://www.ncbi.nlm.nih.gov/pubmed/17553260
http://dx.doi.org/10.3201/eid1305.061124
_version_ 1782171505112645632
author Delaney, J. A. Chris
Dial, Sandra
Barkun, Alan
Suissa, Samy
author_facet Delaney, J. A. Chris
Dial, Sandra
Barkun, Alan
Suissa, Samy
author_sort Delaney, J. A. Chris
collection PubMed
description In a population-based case-control study of community-acquired Clostridium difficile–associated disease (CDAD), we matched 1,233 cases to 12,330 controls. CDAD risk increased 3-fold with use of any antimicrobial agent and 6-fold with use of fluoroquinolones. Prior use of antimicrobial agent did not affect risk for CDAD after 6 months.
format Text
id pubmed-2738472
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-27384722009-09-10 Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK Delaney, J. A. Chris Dial, Sandra Barkun, Alan Suissa, Samy Emerg Infect Dis Dispatch In a population-based case-control study of community-acquired Clostridium difficile–associated disease (CDAD), we matched 1,233 cases to 12,330 controls. CDAD risk increased 3-fold with use of any antimicrobial agent and 6-fold with use of fluoroquinolones. Prior use of antimicrobial agent did not affect risk for CDAD after 6 months. Centers for Disease Control and Prevention 2007-05 /pmc/articles/PMC2738472/ /pubmed/17553260 http://dx.doi.org/10.3201/eid1305.061124 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Delaney, J. A. Chris
Dial, Sandra
Barkun, Alan
Suissa, Samy
Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title_full Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title_fullStr Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title_full_unstemmed Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title_short Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
title_sort antimicrobial drugs and community–acquired clostridium difficile–associated disease, uk
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738472/
https://www.ncbi.nlm.nih.gov/pubmed/17553260
http://dx.doi.org/10.3201/eid1305.061124
work_keys_str_mv AT delaneyjachris antimicrobialdrugsandcommunityacquiredclostridiumdifficileassociateddiseaseuk
AT dialsandra antimicrobialdrugsandcommunityacquiredclostridiumdifficileassociateddiseaseuk
AT barkunalan antimicrobialdrugsandcommunityacquiredclostridiumdifficileassociateddiseaseuk
AT suissasamy antimicrobialdrugsandcommunityacquiredclostridiumdifficileassociateddiseaseuk

Ejemplares similares